Retroviral vectors derived from the Moloney murine leukemia virus have been used in
successful and promising gene therapy clinical trials. However, platforms for their large …

Retroviral-mediated gene transfer is the most attractive modality for gene transfer into
hematopoietic stem cells. However, transduction efficiency has been low using amphotropic …

Genetically modified cells of haematopoietic and lymphocytic lineages could provide
potentially curative treatments for a wide range of inherited and acquired diseases …

Vector-containing medium harvested from murine packaging cell lines has been shown to
contain factors that can negatively influence the transduction and maintenance of …

Many diseases might be treated by gene therapy targeted to the hematopoietic system, but
low rates of gene transfer achieved in humans and large animals have limited the …

A variety of genetic and acquired diseases could conceivably be treated by gene therapy
targeted to hematopoietic stem cells (HSC). Inevitably, the effort to develop reliable methods …

We report increased transduction of human hematopoietic progenitor cells through a
combination of novel retroviral vector packaging cell lines, and improved vector supernatant …

OBJECTIVE: Current protocols of retroviral gene transfer into murine hematopoietic stem
cells (HSC) result in variable gene transfer efficiency and involve various procedures that …

Defined serum-free conditions have great conceptual advantages for the biological safety
and standardization of clinical gene transfer into hematopoietic stem cells. In the only study …

Human hematopoietic stem cells genetically modified by retroviral-mediated gene transfer
may offer new treatment options for patients with genetic disease. The potential of gene …